EGX358

EGX358 is a potent and highly selective small molecule agonist of the estrogen receptor beta (ERβ), developed to treat symptoms associated with menopause, including hot flashes and memory decline. It demonstrates approximately 750-fold selectivity for ERβ over estrogen receptor alpha (ERα), aiming to provide the cognitive and vasomotor benefits of hormone replacement therapy while minimizing risks such as breast cancer or adverse metabolic effects. In preclinical studies, EGX358 improved object recognition memory and reduced drug-induced hot flashes in ovariectomized mouse models without stimulating proliferation in ER+ breast cancer cells or causing organ toxicity. The compound does not inhibit primary liver enzymes at concentrations far exceeding its effective dose for ERβ activation. Estrigenix Therapeutics is developing EGX358 primarily as an oral therapy for menopausal women[2][3][4][6].